Monte Rosa Therapeutics Inc (GLUE) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Monte Rosa Therapeutics Inc stock (GLUE) is currently trading at $15.71. Monte Rosa Therapeutics Inc PS ratio (Price-to-Sales) is 10.11. Analyst consensus price target for GLUE is $32.33. WallStSmart rates GLUE as Sell.
- GLUE PE ratio analysis and historical PE chart
- GLUE PS ratio (Price-to-Sales) history and trend
- GLUE intrinsic value — DCF, Graham Number, EPV models
- GLUE stock price prediction 2025 2026 2027 2028 2029 2030
- GLUE fair value vs current price
- GLUE insider transactions and insider buying
- Is GLUE undervalued or overvalued?
- Monte Rosa Therapeutics Inc financial analysis — revenue, earnings, cash flow
- GLUE Piotroski F-Score and Altman Z-Score
- GLUE analyst price target and Smart Rating
Monte Rosa Therapeutics Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Monte Rosa Therapeutics Inc (GLUE) · 8 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in institutional own.. Concerns around return on equity and operating margin. Significant fundamental concerns warrant caution or avoidance.
Monte Rosa Therapeutics Inc (GLUE) Key Strengths (1)
87.21% of shares held by major funds and institutions
Supporting Valuation Data
Monte Rosa Therapeutics Inc (GLUE) Areas to Watch (7)
Company is destroying shareholder value
Losing money on operations
Revenue declining -95.40%, a shrinking business
Company is losing money with a negative profit margin
Very expensive at 10.1x annual revenue
Very expensive at 5.4x book value
Small-cap company with higher risk but more growth potential
Supporting Valuation Data
Monte Rosa Therapeutics Inc (GLUE) Detailed Analysis Report
Overall Assessment
This company scores 16/100 in our Smart Analysis, earning a F grade. Out of 8 metrics analyzed, 1 register as strengths (avg 10.0/10) while 7 fall into concern territory (avg 1.3/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Institutional Own..
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Revenue Growth. Some valuation metrics including Price/Sales (10.11), Price/Book (5.37) suggest expensive pricing. Growth concerns include Revenue Growth at -95.40%, which may limit upside. Profitability pressure is visible in Return on Equity at -16.90%, Operating Margin at -1788.00%, Profit Margin at -31.20%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -16.90% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -95.40% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
GLUE Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
GLUE's Price-to-Sales ratio of 10.11x sits near its historical average of 9.15x (70th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 51% below its historical high of 20.69x set in Jan 2026, and 140% above its historical low of 4.21x in May 2025. Over the past 12 months, the PS ratio has expanded from ~5.1x, reflecting growing market expectations outpacing revenue growth.
WallStSmart Analysis Synopsis
Data-driven financial summary for Monte Rosa Therapeutics Inc (GLUE) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Monte Rosa Therapeutics Inc is in a turnaround phase, with management focused on restoring profitability. Revenue reached 124M with 95% decline year-over-year. The company is currently unprofitable, posting a -31.2% profit margin.
Key Findings
Debt-to-equity ratio of 0.16 indicates a conservative balance sheet with 208M in cash.
Spending 32% of revenue (40M) on R&D, reinforcing its commitment to innovation and future growth.
Revenue contracted 95% YoY. Worth determining whether this is cyclical or structural.
The company is unprofitable with a -31.2% profit margin. The path to breakeven will be the key catalyst.
What to Watch Next
Volatility is elevated with a beta of 1.64, so expect amplified moves relative to the broader market.
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Monte Rosa Therapeutics Inc.
Bottom Line
Monte Rosa Therapeutics Inc is in turnaround mode. The path to profitability remains the critical question. Speculative investors may see opportunity in the recovery story, but conservative investors should wait for consistent positive earnings before committing capital.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Monte Rosa Therapeutics Inc(GLUE)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Monte Rosa Therapeutics, Inc., a biopharmaceutical company, is dedicated to developing new precision small molecule drugs that employ the body's natural mechanisms to selectively break down therapeutically relevant proteins. The company is headquartered in Boston, Massachusetts.